Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.68 USD | +0.98% | -1.28% | -17.69% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.69% | 11.49B | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-19.27% | 29.48B | |
+57.86% | 25.43B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B | |
+2.29% | 7.67B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte : MorphoSys Dose First Patient in Late-Stage Study of Lymphoma Drug Candidate